Thanks to some big-name deals over the past year, Ambrx could rake in nearly $1 billion in licensing for its antibody drug conjugates, but the company hasn't lost sight of its in-house development, now partnering with WuXi PharmaTech and a Chinese drugmaker to advance a breast cancer treatment.
Gold nanoparticles, because of several inherent characteristics, make excellent drug delivery vehicles, and scientists around the world are now studying the way the tiny particles penetrate cell membranes based on their positive or negative surface charges.
As the top cancer researchers gather in Chicago, the world's largest CRO is weighing in on how best to steer the future of oncology drug development, arguing that picking the right patients and biomarkers in early stages can mean the difference between a blockbuster and a late-phase failure.
The industry is abuzz about the breakthrough potential of new immunotherapies to restore immune attacks on cancers
Qiagen has licensed a few a cancer biomarkers the company said will help expand its heft in the lucrative companion diagnostics world, targeting gene expressions that jibe with in-development therapies.
Researchers in Germany have created nanoparticles that respond to red light as a trigger to release chemotherapy at the site of a tumor.
The preclinical CRO Cenix BioScience has struck a deal to work with Germany's Debiopharm, putting its experts to work finding predictive biomarkers that can be used to advance the biotech's cancer drug candidates.
German CRO Cenix BioScience has agreed to handle preclinical work for Debiopharm's oncology pipeline, using its high-content assays to identify biomarkers.
With the big American Society of Clinical Oncology meeting coming up in two weeks, anticipation about the coming onslaught of data is mounting. Last night, ASCO released some key abstracts for studies to be presented at the meeting, offering an aperitif to oncology-drug followers. Here is a sampling of news, some from our sister publication FierceBiotech.
Bristol-Myers Squibb will collaborate with Adaptive Biotechnologies to develop immunological biomarkers for cancer, representing another step forward in the development of personalized medicine.